Pacific Edge Limited
Recent research View all research
About Pacific Edge Limited
Pacific Edge (PEB) is a cancer diagnostics company in the early stages of commercialising its first product, Cxbladder. Investors continue to require patience, with the large US market challenging to secure reimbursement. Changing established clinical processes takes time, albeit early signs remain encouraging. PEB is a speculative risk stock, reliant on converting key groups to commercial customers, with timing highly unpredictable. Its cash balance offers limited flexibility, however, the prize is large and things could change quickly.
Latest Pacific Edge Limited research